gabapentin has been researched along with Low Back Ache in 34 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic low back pain (CLBP) is a global health problem, and gabapentin and pregabalin are often used in the treatment of patients without associated radiculopathy or neuropathy." | 9.41 | Pregabalin and gabapentin for chronic low back pain without radiculopathy: a systematic review. ( Oliveira, CAC; Poetscher, AW; Tatit, RT, 2023) |
| "This SR provides clear evidence for lack of effectiveness of pregabalin and gabapentin for sciatica pain management." | 9.22 | A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain. ( Carbonell-Sanchís, R; Díaz-Cambronero, JI; Giménez-Campos, MS; López-Briz, E; Pimenta-Fermisson-Ramos, P; Ruíz-García, V, 2022) |
| "Gabapentin is prescribed for analgesia in chronic low back pain, yet there are no controlled trials supporting this practice." | 9.22 | A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. ( Abramson, IS; Atkinson, JH; Capparelli, EV; Funk, SD; Gamst, A; Garfin, SR; Matthews, SC; Patel, SM; Rutledge, TR; Slater, MA; Wallace, MS; Wetherell, JL; Wolfson, T; Zisook, S, 2016) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Gabapentin is an effective therapeutic alternative for chronic low back pain, indicated in several guidelines for treating neuropathic pain as first-line medication." | 8.31 | Pharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: a [99mTc]Tc-ECD SPECT study. ( Alexandre-Santos, L; Coelho, EB; Dach, F; Della Pasqua, O; Lanchote, VL; Lia, EN; Papassidero, P; Trevisan, AC; Wichert-Ana, L, 2023) |
| "Radicular low back pain (rLBP) is often treated off-label with gabapentin or by chiropractors using chiropractic spinal manipulative therapy (CSMT)." | 8.31 | Association between chiropractic spinal manipulation and gabapentin prescription in adults with radicular low back pain: retrospective cohort study using US data. ( Casselberry, RM; Cupler, ZA; Dusek, JA; Perez, JA; Srinivasan, R; Trager, RJ, 2023) |
| " They necessitate prolonged use and are associated with adverse effects and increased cost." | 6.55 | Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2017) |
| "Neuropathic pain is more severe, with significant disability." | 6.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "Chronic low back pain (CLBP) is a global health problem, and gabapentin and pregabalin are often used in the treatment of patients without associated radiculopathy or neuropathy." | 5.41 | Pregabalin and gabapentin for chronic low back pain without radiculopathy: a systematic review. ( Oliveira, CAC; Poetscher, AW; Tatit, RT, 2023) |
| "Gabapentin has an established, favorable safety profile and has been shown to be effective in various animal models and human studies of chronic neuropathic pain." | 5.31 | Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases. ( Braverman, DL; Lenrow, DA; Slipman, CW, 2001) |
| "A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy." | 5.30 | Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019) |
| "This SR provides clear evidence for lack of effectiveness of pregabalin and gabapentin for sciatica pain management." | 5.22 | A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain. ( Carbonell-Sanchís, R; Díaz-Cambronero, JI; Giménez-Campos, MS; López-Briz, E; Pimenta-Fermisson-Ramos, P; Ruíz-García, V, 2022) |
| "Gabapentin is prescribed for analgesia in chronic low back pain, yet there are no controlled trials supporting this practice." | 5.22 | A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. ( Abramson, IS; Atkinson, JH; Capparelli, EV; Funk, SD; Gamst, A; Garfin, SR; Matthews, SC; Patel, SM; Rutledge, TR; Slater, MA; Wallace, MS; Wetherell, JL; Wolfson, T; Zisook, S, 2016) |
| "To evaluate whether an epidural steroid injection or gabapentin is a better treatment for lumbosacral radiculopathy." | 5.20 | Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. ( Bicket, MC; Cohen, SP; Gordin, V; Griffith, SR; Guthmiller, KB; Hanling, S; Hayek, S; Kurihara, C; Pasquina, PF; Veizi, E; Vorobeychik, Y; White, MA; White, RL; Zhao, Z, 2015) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off-label uses." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| "Gabapentin is an effective therapeutic alternative for chronic low back pain, indicated in several guidelines for treating neuropathic pain as first-line medication." | 4.31 | Pharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: a [99mTc]Tc-ECD SPECT study. ( Alexandre-Santos, L; Coelho, EB; Dach, F; Della Pasqua, O; Lanchote, VL; Lia, EN; Papassidero, P; Trevisan, AC; Wichert-Ana, L, 2023) |
| "Radicular low back pain (rLBP) is often treated off-label with gabapentin or by chiropractors using chiropractic spinal manipulative therapy (CSMT)." | 4.31 | Association between chiropractic spinal manipulation and gabapentin prescription in adults with radicular low back pain: retrospective cohort study using US data. ( Casselberry, RM; Cupler, ZA; Dusek, JA; Perez, JA; Srinivasan, R; Trager, RJ, 2023) |
| " They necessitate prolonged use and are associated with adverse effects and increased cost." | 2.55 | Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2017) |
| "Neuropathic pain is more severe, with significant disability." | 2.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| " This study underscores our previous findings that eToims is safe and efficacious for long-term use in CRMP." | 1.43 | Chronic refractory myofascial pain and denervation supersensitivity as global public health disease. ( Bruyninckx, F; Chu, J; Neuhauser, DV, 2016) |
| "The effect of disc degeneration on behavioral measures of chronic pain has not been evaluated in this model." | 1.37 | Behavioral signs of chronic back pain in the SPARC-null mouse. ( Millecamps, M; Sage, EH; Stone, LS; Tajerian, M, 2011) |
| "Gabapentin has an established, favorable safety profile and has been shown to be effective in various animal models and human studies of chronic neuropathic pain." | 1.31 | Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases. ( Braverman, DL; Lenrow, DA; Slipman, CW, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 8 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Giménez-Campos, MS | 1 |
| Pimenta-Fermisson-Ramos, P | 1 |
| Díaz-Cambronero, JI | 1 |
| Carbonell-Sanchís, R | 1 |
| López-Briz, E | 1 |
| Ruíz-García, V | 1 |
| Kwon, DY | 1 |
| Kwak, SG | 1 |
| Kim, DH | 1 |
| Papassidero, P | 1 |
| Wichert-Ana, L | 1 |
| Lia, EN | 1 |
| Alexandre-Santos, L | 1 |
| Trevisan, AC | 1 |
| Coelho, EB | 1 |
| Della Pasqua, O | 1 |
| Lanchote, VL | 1 |
| Dach, F | 1 |
| Tatit, RT | 1 |
| Poetscher, AW | 1 |
| Oliveira, CAC | 1 |
| Trager, RJ | 1 |
| Cupler, ZA | 1 |
| Srinivasan, R | 1 |
| Casselberry, RM | 1 |
| Perez, JA | 1 |
| Dusek, JA | 1 |
| Korem, S | 1 |
| Gandhi, H | 1 |
| Dayag, DB | 1 |
| Knezevic, NN | 1 |
| Aijaz, T | 1 |
| Camacho-Ortega, A | 1 |
| Candido, KD | 1 |
| Read, SH | 1 |
| Giannakeas, V | 1 |
| Pop, P | 1 |
| Bronskill, SE | 1 |
| Herrmann, N | 1 |
| Chen, S | 1 |
| Luke, MJ | 1 |
| Wu, W | 1 |
| McCarthy, LM | 1 |
| Austin, PC | 1 |
| Normand, SL | 1 |
| Gurwitz, JH | 1 |
| Stall, NM | 1 |
| Savage, RD | 1 |
| Rochon, P | 1 |
| Shanthanna, H | 2 |
| Gilron, I | 2 |
| Rajarathinam, M | 2 |
| AlAmri, R | 2 |
| Kamath, S | 2 |
| Thabane, L | 2 |
| Devereaux, PJ | 2 |
| Bhandari, M | 2 |
| Hwang, CJ | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Min, SH | 1 |
| Park, KW | 1 |
| Seo, HY | 1 |
| Song, KS | 1 |
| Goodman, CW | 1 |
| Brett, AS | 1 |
| Leal Rato, M | 1 |
| Duarte, GS | 1 |
| Ferreira, JJ | 1 |
| Robertson, K | 1 |
| Marshman, LAG | 1 |
| Plummer, D | 1 |
| Gialanella, B | 1 |
| Prometti, P | 1 |
| Ferlucci, C | 1 |
| Kantito, S | 2 |
| Tantisiriwat, N | 1 |
| Piravej, K | 1 |
| Cohen, SP | 1 |
| Hanling, S | 1 |
| Bicket, MC | 1 |
| White, RL | 1 |
| Veizi, E | 1 |
| Kurihara, C | 1 |
| Zhao, Z | 1 |
| Hayek, S | 1 |
| Guthmiller, KB | 1 |
| Griffith, SR | 1 |
| Gordin, V | 1 |
| White, MA | 1 |
| Vorobeychik, Y | 1 |
| Pasquina, PF | 1 |
| Pi, ZB | 1 |
| Lin, H | 1 |
| He, GD | 1 |
| Cai, Z | 1 |
| Xu, XZ | 1 |
| Chu, J | 1 |
| Bruyninckx, F | 1 |
| Neuhauser, DV | 1 |
| Pirbudak, L | 1 |
| Ciçek, H | 1 |
| Işik, M | 1 |
| Zer, Y | 1 |
| Atkinson, JH | 1 |
| Slater, MA | 1 |
| Capparelli, EV | 1 |
| Patel, SM | 1 |
| Wolfson, T | 1 |
| Gamst, A | 1 |
| Abramson, IS | 1 |
| Wallace, MS | 1 |
| Funk, SD | 1 |
| Rutledge, TR | 1 |
| Wetherell, JL | 1 |
| Matthews, SC | 1 |
| Zisook, S | 1 |
| Garfin, SR | 1 |
| Ko, S | 1 |
| Kim, S | 1 |
| Kim, J | 1 |
| Oh, T | 1 |
| Gatti, A | 1 |
| Sabato, AF | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| Yildirim, K | 1 |
| Deniz, O | 1 |
| Gureser, G | 1 |
| Karatay, S | 1 |
| Ugur, M | 1 |
| Erdal, A | 1 |
| Senel, K | 1 |
| Millecamps, M | 1 |
| Tajerian, M | 1 |
| Sage, EH | 1 |
| Stone, LS | 1 |
| Strohmeier, M | 1 |
| Lee, TJ | 1 |
| Micucci, CJ | 1 |
| Nease, EK | 1 |
| Tuten, HR | 1 |
| Barrueto, F | 1 |
| Green, J | 1 |
| Howland, MA | 1 |
| Hoffman, RS | 1 |
| Nelson, LS | 1 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Heartsill, LG | 1 |
| Brown, TM | 1 |
| Forde, G | 1 |
| Rosenberg, JM | 1 |
| Harrell, C | 1 |
| Ristic, H | 1 |
| Werner, RA | 1 |
| de Rosayro, AM | 1 |
| Braverman, DL | 1 |
| Slipman, CW | 1 |
| Lenrow, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100] | Phase 4 | 108 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy[NCT01495923] | 145 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| Efficacy of Antidepressants in Chronic Back Pain[NCT00108550] | Phase 2 | 108 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This outcome measure compares the average back pain at baseline to the average back pain 1 month after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 1 month fromt he start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 3.5 |
| Gabapentin | 3.6 |
This outcome measure compares the average back pain at baseline to the average back pain at 3 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 3 months from the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 3.9 |
| Gabapentin | 3.7 |
This outcome measure compares the average leg pain at baseline to the average leg pain 1 month after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 1 month after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 3.3 |
| Gabapentin | 3.7 |
This outcome measure compares the average leg pain at baseline to the average leg pain 3 month after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 3 months from the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 3.7 |
| Epidural Steroid | 3.4 |
Functional capacity measured using Oswestry disability index. The range of possible scores for Oswestry Disability Index are 0-100. 0 is equated with no disability and 100 is the maximum disability possible. (NCT01495923)
Timeframe: 1 month after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 32.6 |
| Gabapentin | 29.6 |
Functional capacity measured using Oswestry disability index. The range of possible scores for Oswestry Disability Index are 0-100. 0 is equated with no disability and 100 is the maximum disability possible. (NCT01495923)
Timeframe: 3 months after the start of treatment
| Intervention | participants (Mean) |
|---|---|
| Epidural Steroid Injection | 33.6 |
| Gabapentin | 29.6 |
This is a measure of participants that proceeded to surgery within a year of enrollment (NCT01495923)
Timeframe: Measured within the year of enrollment in the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Epidural Steroid Injection | 9 |
| Gabapentin | 10 |
This outcome measure compares the worst back pain at baseline to the worst back pain at 1 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 1 month from the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 5.1 |
| Gabapentin | 5.4 |
This outcome measure compares the worst back pain at baseline to the worst back pain at 3 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 5.6 |
| Gabapentin | 5.6 |
This outcome measure compares the average leg pain at baseline to the average leg pain 1 month after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 1 month from the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 4.9 |
| Gabapentin | 5.8 |
This outcome measure compares the worst leg pain at baseline to the worst leg pain at 3 months after the start of treatment. This is measured using the Numeric Pain Scale. The Numeric Pain Scale ranges from 0-10. 0 being no pain at all and 10 being the worst imaginable pain possible. The epidural steroid injection group is compared to the gabapentin group. (NCT01495923)
Timeframe: 3 months from the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Epidural Steroid Injection | 5.2 |
| Gabapentin | 5.5 |
"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The single values reported below represent adjusted means of scores over all time points." (NCT00108550)
Timeframe: Baseline to Week 12 with Interim Measurement at Weeks 1, 2, 3, 4, 5, 7 and 9
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 7.50 |
| Gabapentin | 6.96 |
"Self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor word anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. Prior to analysis an order-preserving mean-matching variance-stabilizing transformation was applied to this measure placing it on a continuous 0-1.5 scale. The single values reported below represent adjusted means of transformed pain intensity over all time points." (NCT00108550)
Timeframe: Baseline to Week 12 with Interim Measurement at Weeks 1, 2, 3, 4, 5, 7 and 9
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.6683 |
| Gabapentin | 0.6988 |
8 reviews available for gabapentin and Low Back Ache
| Article | Year |
|---|---|
A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain.
Topics: Adolescent; Adult; Analgesics; Gabapentin; Humans; Low Back Pain; Pregabalin; Sciatica | 2022 |
Pregabalin and gabapentin for chronic low back pain without radiculopathy: a systematic review.
Topics: Celecoxib; Gabapentin; Humans; Low Back Pain; Pregabalin; Radiculopathy | 2023 |
Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; England; Gabapentin; gamma-Aminobutyric Acid; Human | 2017 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials.
Topics: Amines; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Low | 2016 |
[IGOST guideline for pharmacotherapy of low back pain].
Topics: Amines; Aminopyridines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; | 2010 |
Pharmacologic treatment for low back pain: one component of pain care.
Topics: Acetaminophen; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-S | 2010 |
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis; | 2007 |
11 trials available for gabapentin and Low Back Ache
| Article | Year |
|---|---|
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum | 2019 |
Comparison of the effectiveness between generic and original form of gabapentin for pain relief in suspected neuropathic component of low back pain.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drugs, Generic; Female; Gabapentin; ga | 2014 |
Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study.
Topics: Adult; Amines; Analgesics; Analysis of Variance; Anti-Inflammatory Agents; Cyclohexanecarboxylic Aci | 2015 |
Randomized and controlled prospective trials of Ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia.
Topics: Administration, Oral; Adult; Aged; Amines; Amitriptyline; Analgesics; Celecoxib; Cyclohexanecarboxyl | 2015 |
The effect of tramadol and tramadol + gabapentin combination in patients with lumbar disc herniation after epidural steroid injection.
Topics: Administration, Oral; Adult; Amines; Analgesics; Anesthetics, Local; Bupivacaine; Cyclohexanecarboxy | 2015 |
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component.
Topics: Adult; Aged; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Disability Evaluation; D | 2016 |
The Effectiveness of Oral Corticosteroids for Management of Lumbar Radiating Pain: Randomized, Controlled Trial Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; F | 2016 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality.
Topics: Administration, Oral; Adult; Amines; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
The effect of gabapentin on neuropathic pain.
Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam | 1997 |
15 other studies available for gabapentin and Low Back Ache
| Article | Year |
|---|---|
Comparing the therapeutic effects of pregabalin and gabapentin after transforaminal epidural nerve block in lumbar radiculopathy.
Topics: Gabapentin; Humans; Injections, Epidural; Low Back Pain; Lumbar Vertebrae; Nerve Block; Pregabalin; | 2022 |
Pharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: a [99mTc]Tc-ECD SPECT study.
Topics: Adult; Brain; Gabapentin; Humans; Low Back Pain; Tomography, Emission-Computed, Single-Photon | 2023 |
Association between chiropractic spinal manipulation and gabapentin prescription in adults with radicular low back pain: retrospective cohort study using US data.
Topics: Adult; Chiropractic; Female; Gabapentin; Humans; Low Back Pain; Male; Manipulation, Spinal; Middle A | 2023 |
Guillain-Barré syndrome associated with COVID-19 disease.
Topics: Analgesics; Betacoronavirus; Brain; Coronavirus Infections; COVID-19; Diagnosis, Differential; Femal | 2020 |
A Retrospective Analysis of Gabapentinoid and Opioids to Opioid Monotherapy for Pain Relief in Patients with Chronic Neck and Low Back Pain.
Topics: Analgesics, Opioid; Gabapentin; Humans; Low Back Pain; Pregabalin; Retrospective Studies | 2021 |
Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diuretics; Edema; Female; Gabapentin; Humans; Inappropriate | 2021 |
Proper or Improper Use of the Crossover Design in Clinical Trials in Chronic Sciatica?
Topics: Adult; Cross-Over Studies; Gabapentin; Humans; Low Back Pain; Pregabalin; Sciatica | 2019 |
Proper or Improper Use of the Crossover Design in Clinical Trials in Chronic Sciatica?-Reply.
Topics: Adult; Cross-Over Studies; Gabapentin; Humans; Low Back Pain; Pregabalin; Sciatica | 2019 |
Low back pain radiating to the leg: an atypical cause.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclohexanecarbox | 2013 |
Chronic refractory myofascial pain and denervation supersensitivity as global public health disease.
Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Denervation; Electric Stimulation The | 2016 |
Behavioral signs of chronic back pain in the SPARC-null mouse.
Topics: Age Factors; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Chronic Diseas | 2011 |
Hip pain as initial presentation for varicella-zoster infection in an adolescent male.
Topics: Acyclovir; Adolescent; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Diagnosis, | 2011 |
Gabapentin withdrawal presenting as status epilepticus.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2002 |
Use of gabapentin for rest pain in chronic critical limb ischemia.
Topics: Amines; Analgesics; Bed Rest; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2005 |
Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis | 2001 |